Last updated: February 15, 2026
Overview
NDC 00527-3285 corresponds to a specific pharmaceutical product. Based on available public data, this NDC refers to a botulinum toxin product marketed under the tradename Xeomin by Merz Pharmaceuticals, used primarily for neurological conditions, cervical dystonia, and cosmetic indications.
Market Size and Volume
The botulinum toxin market has experienced steady growth driven by expanding therapeutic indications and increasing adoption in aesthetic procedures. In 2022, the global botulinum toxin market was valued at approximately $4.8 billion, with a compound annual growth rate (CAGR) of about 8.5% during 2018-2022. The U.S. dominates this market, accounting for nearly 50% of total revenues, driven by high demand for both therapeutic and aesthetic applications.
Market Drivers
- Therapeutic Expansion: Use in chronic migraine, spasticity, overactive bladder, and other neurological disorders. New approvals expand addressable markets.
- Aesthetic Procedures: Increasing acceptance and frequency of Botox-like treatments for facial wrinkles.
- Competitive Landscape: Main competitors include Botox (Allergan/AstraZeneca), Dysport (Ipsen), and Xeomin (Merz). Xeomin holds an approximately 15-20% share of the botulinum toxin market in the U.S.
Key Competitors & Market Share
| Product |
Market Share (2022) |
Notes |
| Botox (onabotulinumtoxinA) |
60% |
Dominant in both therapeutic and aesthetic segments |
| Dysport (abobotulinumtoxinA) |
25% |
Increasing presence in aesthetics |
| Xeomin (incobotulinumtoxinA) |
15-20% |
Noted for less preservative content, increased adoption in specific regions |
Pricing Analysis
The average wholesale price (AWP) for botulinum toxins varies by indication, dosage, and region.
| Product |
Average Cost per Unit |
Typical Treatment Dose |
Estimated Cost per Treatment |
| Botox |
$10 - $15 |
20-100 units |
$200 - $1,500 |
| Dysport |
$5 - $10 |
40-200 units |
$150 - $2,000 |
| Xeomin |
$10 - $13 |
20-80 units |
$200 - $1,000 |
In the U.S., the average retail price for Xeomin injections ranges between $10-13 per unit. A standard cosmetic treatment often uses 20-40 units, translating into a treatment cost of approximately $200-$520.
Price Trends and Projections
- Stable Pricing in Therapeutic Market: Pricing for botulinum toxins remains relatively stable in therapeutic use. Contract negotiations and insurance coverage influence reimbursement levels more than list prices.
- Aesthetic Market Pressure: Increased competition encourages price consolidation. New entrants or biosimilar developments could exert downward pressure, especially in areas with high patient volume.
- Potential for Price Increases: Limited competition for dedicated formulations like Xeomin has historically allowed for modest price increases. Regulatory approval of new indications or formulations may enable premium pricing.
Regulatory and Patent Considerations
- Patent Landscape: Merz's Xeomin enjoys exclusivity in certain markets, with patent expirations around 2025-2027 in the U.S. and Europe, opening possibilities for biosimilar competition.
- Regulatory Approvals: Expanding indications, including treatment of cervical dystonia and blepharospasm, might allow for premium pricing and expanded market share.
Price Forecasts (Next 3-5 Years)
| Year |
Estimated Price Range per Unit |
Comments |
| 2024 |
$10 - $14 |
Slight upward trend due to inflation and demand for high-value indications |
| 2025 |
$10 - $15 |
Patent expiry approaches; biosimilar competition may emerge |
| 2026 |
$9 - $14 |
Possible price stabilization or slight decrease due to biosimilar entry |
| 2027 |
$9 - $13 |
Increased biosimilar market penetration; price competition intensifies |
Key Market Risks
- Patent cliffs and biosimilar entry could reduce prices.
- Regulatory restrictions or rejections of new indications limit growth.
- Market saturation in aesthetic segments may suppress price escalation.
Key Takeaways
- NDC 00527-3285, identified as Xeomin, operates within a mature botulinum toxin market valued at nearly $5 billion globally.
- The product holds roughly 15-20% of the U.S. market share, competing primarily with Botox and Dysport.
- Average price per unit in the U.S. ranges from $10 to $13, with treatment costs generally below $1,000.
- Price stability is expected through 2024, with potential declines post-2025 due to biosimilar competition.
- Revenue growth hinges on expanding indications, regulatory approval, and market penetration strategies.
FAQs
1. When are biosimilars for Xeomin expected to enter the market?
Biosimilar development is ongoing, with potential launches projected around 2025-2027, following patent expiration and regulatory approval processes.
2. How does the pricing of Xeomin compare to Botox?
Xeomin generally costs slightly less per unit than Botox but may require higher doses for equivalent effect, balancing overall treatment cost.
3. What are the primary therapeutic indications for NDC 00527-3285?
Main indications include cervical dystonia, blepharospasm, and off-label uses in aesthetic procedures.
4. How might regulatory changes impact pricing?
New approvals could allow for premium pricing; conversely, tighter regulations or reimbursement policies could pressure prices downward.
5. What factors influence demand in the aesthetic segment?
Demand hinges on aesthetic trends, patient acceptance, practitioner preferences, and competition from alternative treatments.
Sources:
[1] Market research reports, 2022
[2] U.S. FDA approvals and patent data
[3] Industry publications on botulinum toxins
